A Phase 2 interventional study of Vamorolone 0.25 mg/kg/day and Vamorolone 0.75 mg/kg/day in Duchenne Muscular Dystrophy, sponsored by ReveraGen BioPharma, Inc.. Completed at 12 sites in 6 countries. Open to male participants aged 4 Years to 6 Years. Per ClinicalTrials.gov, last updated 2019-01-02.
Sponsored by ReveraGen BioPharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.
Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 58th largest by enrollment of the 171 interventional ones that give a count, is one of 15 that started in 2016, is one of 57 in phase 2, and was the 100th registered.
481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
University of Florida · Sites in United States
Ages 6+ · Men only
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
University of Rochester · Sites in United States
Ages 0 days–3 yrs · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.
This study: 4 Years to 6 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 57 · Phase 2 90 · Phase 3 40 · Phase 4 5
First in 2000; this study’s year is marked. 15 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is above the median of 26 across 332 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 25 across the 171 interventional studies, 75 across the 55 observational. Of the 160 that completed or were terminated, 78 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 232 have an industry lead sponsor. The 10 most frequent:
ReveraGen BioPharma, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
ReveraGen BioPharma, Inc. has 5 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
20 of the studies in Muscular Dystrophy, Duchenne with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT06290713University of FloridaVasodilator and Exercise Study for DMD (VASO-REx) | 2026-11 |
| NCT06450639Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | 2026-11-18 |
| NCT03368742Solid Biosciences Inc.Microdystrophin Gene Transfer Study in Adolescents and Children With DMD | 2026-11-30 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 20 to your calendar (.ics) → With an account.
Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether a new medication called vamorolone is safe and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and \< 7 years old.
This study will evaluate the safety and tolerability of a new steroid-like medication called vamorolone in boys with DMD ages ≥ 4 years and \< 7 years. Enrolled participants will take the study medication for 14 days followed by a 14 day follow-up period. The potential effectiveness of vamorolone in treating DMD will also be explored.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has a confirmed (by Central Genetic Counselor) diagnosis of DMD as defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
Drug: Vamorolone 0.25 mg/kg/day
Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
Drug: Vamorolone 0.75 mg/kg/day
Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
Drug: Vamorolone 2.0 mg/kg/day
Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
Drug: Vamorolone 6.0 mg/kg/day
Drug page: Vamorolone
Oral administration of 0.25 mg/kg/day daily for 14 days.
Also known as: VBP15
Drug page: Vamorolone
Oral administration of 0.75 mg/kg/day daily for 14 days.
Also known as: VBP15
Drug page: Vamorolone
Oral administration of 2.0 mg/kg/day daily for 14 days.
Also known as: VBP15
Drug page: Vamorolone
Oral administration of 6 mg/kg/day daily for 14 days.
Also known as: VBP15
Overall Summary of Adverse Events as Assessed by CTCAE Version 4.03
Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). Serious adverse events were recorded for up to 30 days after the final administration of study drug. Note: Total Number of Treatment Emergent Adverse Events: The total incidences of TEAEs experienced in study; Any Treatment Emergent Adverse Event: TEAEs reported at least once per dose group
Time frame: Adverse events will be recorded from the date of informed consent and through the time of the subject's last study visit. Serious adverse events will be recorded from the date of informed consent and for up to 30 days after final drug administration.
Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Fasting Glucose
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
Time frame: Baseline, Week 2
Serum Pharmacodynamic Biomarkers (Insulin Resistance) -Fasting Glucose
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
Time frame: Baseline, Week 2
Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
Time frame: Baseline , Week 2
Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
Time frame: Baseline, Week 2
Serum Pharmacodynamic Biomarkers (Adrenal Axis Suppression)- First in Morning Cortisol
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
Time frame: Week 2 (pre-dose)
Serum Pharmacodynamics Biomarkers (Bone Turnover) -Osteocalcin
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
Time frame: Baseline, Day 1, Week 2, Week 4
Serum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
Time frame: Baseline Day 1 Week 2 Week 4
Serum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
Time frame: Baseline, Day 1, Week 2, Week 4
Serum Pharmacodynamic Biomarkers (Bone Turnover)-Type I Collagen C-Telopeptides
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
Time frame: Baseline, Day 1, Week 4
Pharmacokinetic (PK) Assessments (Tmax)
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. tmax= time when plasma concentration is at maximum.
Time frame: Day 1, Week 2
Pharmacokinetic (PK) Assessments (AUC Inf)
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. AUC inf= Area under the concentration vs. time curve to time infinity.
Time frame: Day 1, Week 2
Pharmacokinetic (PK) Assessments CL (ml/hr/kg)
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay
Time frame: Day 1, Week 2
Pharmacokinetic (PK) Assessments t(1/2)
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. t1/2= elimination half life.
Time frame: Day 1, Week 2
Pharmacokinetic (PK) Assessments (Cmax)
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay
Time frame: Day 1, Week 2
Metabolites in Safety Testing (MIST) Assessment
A portion of each blood sample of the Week 2 (Day 14) pharmacokinetic assessment time points for the subjects receiving vamorolone 2 mg/kg/day was used for analysis of vamorolone metabolites.
Time frame: Week 2 (Day 14)
| Milestone | Vamorolone 0.25 mg/kg/Day | Vamorolone 0.75 mg/kg/Day | Vamorolone 2.0 mg/kg/Day | Vamorolone 6.0 mg/kg/Day |
|---|---|---|---|---|
| Started | 12 | 0 | 0 | 0 |
| Completed | 12 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Vamorolone 0.25 mg/kg/Day | Vamorolone 0.75 mg/kg/Day | Vamorolone 2.0 mg/kg/Day | Vamorolone 6.0 mg/kg/Day |
|---|---|---|---|---|
| Started | 0 | 12 | 0 | 0 |
| Completed | 0 | 12 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Vamorolone 0.25 mg/kg/Day | Vamorolone 0.75 mg/kg/Day | Vamorolone 2.0 mg/kg/Day | Vamorolone 6.0 mg/kg/Day |
|---|---|---|---|---|
| Started | 0 | 0 | 12 | 0 |
| Completed | 0 | 0 | 12 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Vamorolone 0.25 mg/kg/Day | Vamorolone 0.75 mg/kg/Day | Vamorolone 2.0 mg/kg/Day | Vamorolone 6.0 mg/kg/Day |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 12 |
| Completed | 0 | 0 | 0 | 12 |
| Not completed | 0 | 0 | 0 | 0 |
Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). Serious adverse events were recorded for up to 30 days after the final administration of study drug. Note: Total Number of Treatment Emergent Adverse Events: The total incidences of TEAEs experienced in study; Any Treatment Emergent Adverse Event: TEAEs reported at least once per dose group
| Number of Events | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Total Number of Adverse Events | 16 | 18 | 13 | 11 |
| Total Number of Treatment Emergent Adverse Events | 13 | 13 | 11 | 9 |
| Any Treatment Emergent Adverse Events | 7 | 6 | 8 | 7 |
| Any Drug Related Treatment Emergent Adverse Events | 1 | 2 | 2 | 3 |
| Any CTCAE Grade 3 or Higher TEAE | 0 | 0 | 0 | 0 |
| Discontinuation of Study Drug due to TEAE | 0 | 0 | 0 | 0 |
| Any Serious Treatment Emergent Adverse Events | 0 | 0 | 0 | 0 |
| Death | 0 | 0 | 0 | 0 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
| mg/ dL | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Baseline | 87.5 ± 9.44 | 88.9 ± 18.71 | 89.3 ± 7.91 | 92.3 ± 8.19 |
| Week 2 | 85.3 ± 9.29 | 83.1 ± 6.69 | 89.5 ± 5.20 | 89.2 ± 11.12 |
| Week 2 Change from Baseline | -2.2 ± 10.46 | -5.8 ± 18.92 | 0.2 ± 8.79 | -1.3 ± 9.41 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
| Week 2 % change from Baseline | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Serum Pharmacodynamic Biomarkers (Insulin Resistance) -Fasting Glucose | -1.8 ± 13.07 | -4.2 ± 13.98 | 0.8 ± 9.76 | -1.2 ± 9.80 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
| µIU/mL | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Baseline | 5.54 ± 3.651 | 3.09 ± 2.033 | 3.40 ± 1.548 | 3.96 ± 2.027 |
| Week 2 | 5.29 ± 2.671 | 3.22 ± 1.924 | 3.87 ± 2.118 | 6.73 ± 4.599 |
| Week 2 Change from Baseline | -0.65 ± 2.913 | 0.34 ± 1.289 | 0.47 ± 2.777 | 2.78 ± 4.651 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
| Week 2 % change from Baseline | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin | -5.54 ± 32.622 | 26.07 ± 76.483 | 42.85 ± 107.337 | 83.55 ± 117.064 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
| mcg/dL | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Serum Pharmacodynamic Biomarkers (Adrenal Axis Suppression)- First in Morning Cortisol | 10.425 ± 1.7358 | 9.755 ± 2.7614 | 7.321 ± 3.0322 | 3.010 ± 1.0141 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
| ng/mL | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Baseline | 37.94 ± 11.622 | 35.66 ± 6.800 | 41.17 ± 5.617 | 44.36 ± 5.979 |
| Day 1 | 39.37 ± 14.189 | 35.89 ± 7.526 | 34.93 ± 6.881 | 33.52 ± 9.135 |
| Day 1 Change from Baseline | 1.43 ± 8.197 | 0.23 ± 5.304 | -6.23 ± 10.930 | -11.37 ± 9.137 |
| Week 2 | 38.53 ± 12.025 | 35.10 ± 8.238 | 37.51 ± 8.624 | 29.04 ± 4.853 |
| Week 2 Change from Baseline | 0.58 ± 5.986 | -0.56 ± 7.934 | -3.66 ± 9.818 | -15.32 ± 6.450 |
| Week 4 | 39.20 ± 14.136 | 42.24 ± 8.426 | 47.91 ± 6.648 | 42.81 ± 10.851 |
| Week 4 Change from Baseline | 1.26 ± 5.650 | 6.58 ± 9.341 | 6.74 ± 9.747 | -1.55 ± 11.176 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
| % change from Baseline | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Day 1 Percent Change from Baseline | 3.95 ± 22.015 | 1.41 ± 15.449 | -12.63 ± 25.020 | -25.05 ± 20.228 |
| Week 2 Percent Change from Baseline | 2.48 ± 16.756 | -0.07 ± 22.408 | -7.81 ± 23.664 | -33.87 ± 12.548 |
| Week 4 Percent Change from Baseline | 2.72 ± 14.063 | 20.91 ± 28.644 | 18.74 ± 25.095 | -2.43 ± 25.932 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
| ng/mL | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Baseline | 555.8 ± 184.72 | 480.7 ± 118.20 | 508.2 ± 94.36 | 511.5 ± 106.50 |
| Day 1 | 474.0 ± 116.45 | 443.7 ± 112.38 | 417.1 ± 87.35 | 475.2 ± 147.10 |
| Day 1 Change from Baseline | -81.8 ± 124.24 | -34.5 ± 101.97 | -91.1 ± 64.64 | -36.5 ± 144.04 |
| Week 2 | 443.8 ± 93.86 | 407.8 ± 96.54 | 346.6 ± 68.59 | 303.7 ± 56.38 |
| Week 2 Change from Baseline | -112.0 ± 125.08 | -70.6 ± 123.69 | -161.6 ± 73.52 | -207.8 ± 78.16 |
| Week 4 | 573.8 ± 251.02 | 496.7 ± 117.57 | 492.0 ± 81.92 | 566.3 ± 149.32 |
| Week 4 Change from Baseline | 18.1 ± 153.10 | 21.3 ± 122.87 | -16.2 ± 79.64 | 54.8 ± 118.09 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
| % change from Baseline | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Day 1 Percent Change from Baseline | -12.2 ± 17.07 | -5.4 ± 24.58 | -17.4 ± 12.59 | -5.7 ± 30.76 |
| Week 2 Percent Change from Baseline | -17.5 ± 14.65 | -11.2 ± 29.19 | -30.9 ± 11.80 | -39.9 ± 9.22 |
| Week 4 Percent Change from Baseline | 2.8 ± 25.57 | 7.8 ± 30.86 | -1.4 ± 17.47 | 11.8 ± 28.24 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
| pg/mL | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Baseline | 871.0 ± 160.85 | 935.8 ± 286.50 | 936.8 ± 256.25 | 889.3 ± 186.68 |
| Day 1 | 974.8 ± 252.77 | 940.8 ± 227.60 | 838.3 ± 233.30 | 786.8 ± 331.68 |
| Day 1 Change from Baseline | 72.4 ± 241.87 | -12.9 ± 233.44 | -98.5 ± 237.69 | -115.7 ± 421.04 |
| Week 2 | 963.7 ± 157.68 | 903.3 ± 251.01 | 710.4 ± 180.03 | 625.7 ± 203.19 |
| Week 2 Change from Baseline | 85.0 ± 185.90 | -19.9 ± 266.99 | -226.4 ± 185.99 | -263.7 ± 229.69 |
| Week 4 | 915.9 ± 263.13 | 983.5 ± 298.47 | 949.8 ± 303.76 | 989.2 ± 216.29 |
| Week 4 Change from Baseline | 17.4 ± 267.45 | 34.8 ± 271.50 | 12.9 ± 181.45 | 99.8 ± 211.90 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.
| % change from Baseline | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Day 1 Percent Change from Baseline | 9.9 ± 25.38 | 2.7 ± 23.76 | -8.0 ± 23.93 | -6.7 ± 53.72 |
| Week 2 Percent Change from Baseline | 11.9 ± 20.52 | 2.2 ± 26.44 | -22.5 ± 15.27 | -27.7 ± 26.50 |
| Week 4 Percent Change from Baseline | 3.6 ± 28.96 | 6.8 ± 24.06 | 2.7 ± 19.03 | 14.5 ± 32.98 |
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. tmax= time when plasma concentration is at maximum.
| hour | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Day 1 | 3.6 ± 1.2 | 4.6 ± 2.1 | 2.5 ± 1.3 | 2.7 ± 1.3 |
| Week 2 | 3.8 ± 1.80 | 3.8 ± 2.2 | 2.8 ± 1 | 2.3 ± 0.86 |
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. AUC inf= Area under the concentration vs. time curve to time infinity.
| [(hr)(ng)/mL] | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Day 1 | 118 ± 48 | 379 ± 117 | 761 ± 352 | 3279 ± 1693 |
| Week 2 | 164 ± 61 | 544 ± 155 | 1138 ± 467 | 3606 ± 897 |
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay
| ml/hr/kg | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Day 1 | 2459 ± 897 | 2285 ± 1103 | 2697 ± 1285 | 2320 ± 1375 |
| Week 2 | 1828 ± 919 | 1509 ± 482 | 2047 ± 771 | 1777 ± 476 |
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. t1/2= elimination half life.
| hour | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Day 1 | 2.1 ± 0.85 | 1.8 ± 0.43 | 1.9 ± 0.79 | 1.9 ± 0.95 |
| Week 2 | 1.9 ± 0.96 | 2.1 ± 0.8 | 1.9 ± 1.02 | 1.4 ± 0.35 |
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay
| ng/mL | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Day 1 | 22.9 ± 13.4 | 75.9 ± 25.9 | 199 ± 111 | 855.6 ± 471 |
| Week 2 | 32.2 ± 15.2 | 124.7 ± 42.5 | 252.2 ± 96 | 970 ± 270 |
A portion of each blood sample of the Week 2 (Day 14) pharmacokinetic assessment time points for the subjects receiving vamorolone 2 mg/kg/day was used for analysis of vamorolone metabolites.
| % of total drug related exposure | Dose Level Group 3 |
|---|---|
| M1 | 34.42 ± 2.79 |
| M2 | 1.16 ± 0.06 |
| M3 | 1.21 ± 0.07 |
| M4 | 37.84 ± 3.78 |
| M5 | 2.73 ± 0.17 |
| Vamorolone | 22.64 ± 0.69 |
Collected over Adverse events will be recorded from the date of informed consent and through the time of the subject's last study visit. Serious adverse events will be recorded from the date of informed consent and for up to 30 days after final drug administration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Level Group 1 | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Dose Level Group 2 | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Dose Level Group 3 | 0/12 (0%) | 0/12 (0%) | 8/12 (66.7%) |
| Dose Level Group 4 | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Event | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 |
|---|---|---|---|---|
| Viral Upper Respiratory Tract InfectionInfections and infestations | 3/12 | 2/12 | 1/12 | 0/12 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 0/12 | 3/12 | 0/12 | 0/12 |
| DiarrhoeaGastrointestinal disorders | 1/12 | 0/12 | 1/12 | 2/12 |
| VomitingGastrointestinal disorders | 2/12 | 0/12 | 0/12 | 1/12 |
| Upper-airway cough syndromeRespiratory, thoracic and mediastinal disorders | 0/12 | 2/12 | 0/12 | 0/12 |
| Abdominal PainGastrointestinal disorders | 0/12 | 1/12 | 0/12 | 0/12 |
| Abdominal Pain UpperGastrointestinal disorders | 0/12 | 0/12 | 1/12 | 0/12 |
| ConstipationGastrointestinal disorders | 0/12 | 0/12 | 0/12 | 1/12 |
| Faeces DiscolouredGastrointestinal disorders | 1/12 | 0/12 | 0/12 | 0/12 |
| Lip SwellingGastrointestinal disorders | 1/12 | 0/12 | 0/12 | 0/12 |
| Age, Customized(years) | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Total |
|---|---|---|---|---|---|
| Age | 5.2 ± 1.03 | 4.8 ± 0.83 | 4.7 ± 0.89 | 4.8 ± 0.75 | 4.9 ± 0.87 |
| Sex: Female, Male(Participants) | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 12 | 12 | 12 | 12 | 48 |
| Ethnicity (NIH/OMB)(Participants) | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 3 | 4 |
| Not Hispanic or Latino | 12 | 11 | 12 | 9 | 44 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 1 |
| White | 11 | 10 | 12 | 12 | 45 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | Dose Level Group 1 | Dose Level Group 2 | Dose Level Group 3 | Dose Level Group 4 | Total |
|---|---|---|---|---|---|
| Canada | 3 | 0 | 2 | 2 | 7 |
| Sweden | 0 | 4 | 0 | 0 | 4 |
| United States | 9 | 3 | 2 | 6 | 20 |
| United Kingdom | 0 | 0 | 4 | 2 | 6 |
| Israel | 0 | 3 | 2 | 0 | 5 |
| Australia | 0 | 2 | 2 | 2 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
The record gives a start of Jun 2016, a primary completion of May 2018 and a completion of May 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2019, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vamorolone
Muscular Dystrophy, Duchenne →
ReveraGen BioPharma, Inc.